LJPC
La Jolla Pharmaceutical Company
$6.22
Earnings Summary
Revenue | $10.43Mn |
Net Profits | $0Mn |
Net Profit Margins | 0.02% |
PE Ratio | 38.75 |
Highlights
La Jolla Pharmaceutical Company’s revenue fell -69.46% since last year same period to $10.43Mn in the Q1 2022. On a quarterly growth basis, La Jolla Pharmaceutical Company has generated -14.62% fall in its revenue since last 3-months.
La Jolla Pharmaceutical Company’s net profit fell -99.99% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, La Jolla Pharmaceutical Company has generated -99.95% fall in its net profits since last 3-months.
La Jolla Pharmaceutical Company’s net profit margin fell -99.95% since last year same period to 0.02% in the Q1 2022. On a quarterly growth basis, La Jolla Pharmaceutical Company has generated -99.94% fall in its net profit margins since last 3-months.
La Jolla Pharmaceutical Company’s price-to-earnings ratio after this Q1 2022 earnings stands at 38.75.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the La Jolla Pharmaceutical Company post its latest quarter earnings
EPS Estimate Current Quarter | 0.02 |
EPS Estimate Current Year | 0.02 |
Highlights
La Jolla Pharmaceutical Company’s earning per share (EPS) estimates for the current quarter stand at 0.02 - a 100% jump from last quarter’s estimates.
La Jolla Pharmaceutical Company’s earning per share (EPS) estimates for the current year stand at 0.02.
Key Ratios
Key ratios of the La Jolla Pharmaceutical Company post its Q1 2022 earnings
Earning Per Share (EPS) | -0.15 |
Return on Assets (ROA) | -0.02 |
Return on Equity (ROE) | 0 |
Highlights
La Jolla Pharmaceutical Company’s earning per share (EPS) fell -135.71% since last year same period to -0.15 in the Q1 2022. This indicates that the La Jolla Pharmaceutical Company has generated -135.71% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. La Jolla Pharmaceutical Company’s return on assets (ROA) stands at -0.02.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. La Jolla Pharmaceutical Company’s return on equity (ROE) stands at 0.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-16 | 0.01 | -0.15 | -1600% |
₹0 US Stocks a/c Opening Fee